Neurocrine Biosciences宣布新调查揭示了迟发性运动障碍患者需要常规筛查和早期诊断的需求-动脉网

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

CISION 等信源发布 2025-05-05 20:30



可切换为仅中文







-- Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements

——大多数受访者表示，迟发性运动障碍对他们的日常生活能力产生了负面影响，包括那些患有轻度或中度未控制运动的个体。

SAN DIEGO

圣地亚哥

，

May 5, 2025

2025年5月5日

/PRNewswire/ --

Neurocrine Biosciences, Inc

神经分泌生物科学公司

. (Nasdaq:

.（纳斯达克：

NBIX

) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and reinforcing the need for routine screening, earlier diagnosis and treatment. The findings revealed that 80% of people living with tardive dyskinesia surveyed wished they had been screened for the condition earlier, and 86% wished their provider had discussed available treatment options for their uncontrolled movements sooner..

）今天宣布了由哈里斯民意调查公司开展的一项新调查结果，强调了迟发性运动障碍对患者的深远负面影响，并加强了对常规筛查、早期诊断和治疗的需求。调查结果显示，80%的迟发性运动障碍患者表示希望他们能更早接受筛查，86%的人希望他们的医生能更早讨论针对其不可控运动的可用治疗方案。

The survey results come during Tardive Dyskinesia (TD) Awareness Week,

调查结果恰逢迟发性运动障碍（TD）宣传周，

May 4-10

5月4日-10日

. Established in 2018, TD Awareness Week is dedicated to raising awareness about the physical, social and emotional effects of TD, as well as the importance of routine screening to promote earlier diagnosis and treatment. There are at least 800,000 adults in

成立于2018年的TD意识周致力于提高人们对TD的身体、社交和情感影响的认识，同时强调常规筛查的重要性以促进早期诊断和治疗。至少有80万名成年人在

the United States

美国

affected by TD, yet an estimated 60% remain undiagnosed.

受到TD影响，但据估计仍有60%未被诊断。

2,3

The survey included a total of 150 patients in

调查总共包括150名患者在

the United States

美国

aged 18 years and older who have been diagnosed with TD by a healthcare provider. Participants self-reported the severity of their TD movements, with 75% of respondents reporting that they had mild to moderate uncontrolled movements. Findings reinforce the significant negative impact TD has on patients' daily lives, even among those with mild to moderate involuntary movements..

年龄在18岁及以上的患者，这些患者已被医疗保健提供者诊断为TD。参与者自我报告了他们的TD运动的严重程度，75%的受访者表示他们有轻度到中度的不可控运动。研究结果强调了TD对患者日常生活的显著负面影响，即使是那些有轻度至中度不自主运动的患者也不例外。

'These findings highlight the significant daily challenges faced by people living with tardive dyskinesia,' said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. 'This underscores the importance of regular screening to detect the condition early, ensuring patients can receive appropriate treatment for their involuntary movements, which often cause functional impairment, emotional distress and social difficulties.'.

“这些研究结果突显了迟发性运动障碍患者所面临的严峻日常挑战，”Neurocrine Biosciences首席医疗官Eiry W. Roberts博士说道。“这强调了定期筛查以早期发现该病症的重要性，确保患者能够获得针对其不自主运动的适当治疗，这些症状往往导致功能损害、情绪困扰和社会困难。”

Key findings include

关键发现包括

：

Functional Impact

功能影响

43% of all patients surveyed and 40% of those with mild/moderate TD had asked someone to help with doing daily activities as a result of their TD symptoms.

43% 的受访患者和 40% 的轻度/中度 TD 患者表示，由于他们的 TD 症状，他们曾请求他人帮助完成日常活动。

41% of all patients and 40% of those with mild/moderate TD were unable to perform their job functions as a result of their TD symptoms.

41% 的患者和 40% 的轻度/中度 TD 患者由于 TD 症状而无法履行其工作职能。

Psychological Impact

心理影响

86% of all patients and 87% of those with mild/moderate TD agreed that their movements made them feel judged or stared at.

86% 的患者和 87% 的轻度/中度 TD 患者表示，他们的动作让他们感到被评判或注视。

82% of all patients and 82% of those with mild/moderate TD somewhat or strongly agreed that their uncontrolled movements bring unwanted attention to their underlying mental health condition.

82%的患者以及82%的轻中度TD患者在某种程度上或强烈同意，他们无法控制的动作使人们的注意力转向了其潜在的心理健康状况。

80% of all patients and 82% of those with mild/moderate TD somewhat or strongly agreed that their uncontrolled movements made them feel like others are making incorrect assumptions about them.

80% 的所有患者和 82% 的轻度/中度 TD 患者在某种程度上或强烈同意，他们无法控制的动作让他们觉得别人对他们有错误的看法。

Social Impact

社会影响

Social impacts of TD movements were seen at home and at work. These included:

TD运动在家庭和工作中都产生了社会影响，这些影响包括：

Avoiding others/going out in public (56% of all patients, 55% with mild/moderate TD).

避免与他人接触/外出（所有患者中的56%，轻度/中度TD患者中的55%）。

Avoiding leaving home (44% of all patients, 46% with mild/moderate TD).

避免出门（占所有患者的44%，轻度/中度TD患者占46%）。

Limited professional interactions (40% of all patients, 43% with mild/moderate TD).

有限的专业互动（占所有患者的40%，轻度/中度TD患者占43%）。

Missed work/school (40% of all patients, 34% with mild/moderate TD).

错过工作/学校（所有患者中的40%，轻度/中度TD患者中的34%）。

'The involuntary movements of tardive dyskinesia can profoundly affect individuals physically, socially and emotionally,' said

“迟发性运动障碍的不自主运动可能深刻影响个体的身体、社交和情绪。”

Josie Cooper

乔茜·库珀

, Executive Director of the Movement Disorders Policy Coalition. 'Tardive dyskinesia can often go undiagnosed, but with proactive and routine screening, we can ensure those affected receive the care and support they need to help manage the condition. That's why we are working on a national and state level to improve access to care and resources for those experiencing uncontrolled movements.'.

运动障碍政策联盟执行主任。“迟发性运动障碍常常会未被诊断出来，但通过积极主动和常规的筛查，我们可以确保受影响者获得所需的护理和支持，以帮助管理病情。这就是为什么我们正在国家和州级层面努力改善那些经历无法控制的动作的患者获得护理和资源的机会。”

The findings of the survey also demonstrate a need for continued education regarding TD, particularly among people taking antipsychotic medications, which can cause the abnormal, involuntary and repetitive movements associated with TD. Specifically

调查结果还表明，需要继续对迟发性运动障碍（TD）进行教育，特别是对于那些服用抗精神病药物的人群，因为这类药物可能会导致与TD相关的异常、不自主和重复的运动。具体来说

：

Only 47% of patients state they were informed by their provider about the possibility that their mental health medication(s) could be contributing to their symptoms prior to diagnosis.

只有47%的患者表示，在诊断之前，他们的医生告知他们心理健康药物可能会导致他们的症状。

75% of all patients – and 74% of those with mild/moderate symptoms – were unaware before being diagnosed that their mental health medication(s) could cause TD.

75%的患者——以及74%有轻度/中度症状的患者——在确诊之前并不知道他们的精神健康药物可能导致TD。

83% of people with TD wish they had been encouraged to talk to a healthcare provider about their uncontrolled movements earlier.

83%的TD患者表示，他们希望自己之前被鼓励更早地与医疗服务提供者讨论自己无法控制的动作。

'Regular screening for tardive dyskinesia among patients on antipsychotic therapy is crucial for early detection and management, ultimately leading to better outcomes for patients, their families and care partners,' said Dr. Roberts.

“对于接受抗精神病药物治疗的患者，定期进行迟发性运动障碍的筛查对于早期发现和管理至关重要，最终将为患者、他们的家人和护理伙伴带来更好的结果，”罗伯茨博士说。

The American Psychiatric Association guidelines recommend that any TD movements with a negative impact on patients be treated with a vesicular monoamine transporter 2 inhibitor (VMAT2).

美国精神病学协会指南建议，对患者有负面影响的任何TD运动，应使用囊泡单胺转运体2抑制剂（VMAT2）进行治疗。

Survey Methodology

调查方法论

The research was conducted online in

研究是在网上进行的

the United States

美国

by The Harris Poll on behalf of Neurocrine Biosciences among 150 patients aged 18 or older who have been diagnosed by a healthcare provider with tardive dyskinesia. The survey was conducted

由Neurocrine Biosciences委托The Harris Poll进行，调查对象为150名年满18岁及以上、经医疗保健提供者诊断患有迟发性运动障碍的患者。该调查已实施。

December 12-31, 2024

2024年12月12日-31日

. Raw data were not weighted and are therefore only representative of the individuals who completed the survey. For this study, the patient sample data is accurate to within ±7.9 percentage points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest.

原始数据未加权，因此仅代表完成调查的个人。在本研究中，患者样本数据在95%置信水平下准确至±7.9个百分点以内。在目标调查人群的子集中，该可信区间会更宽。

All sample surveys and polls, whether or not they use probability sampling, are subject to other multiple sources of error which are most often not possible to quantify or estimate, including, but not limited to, coverage error, error associated with nonresponse, error associated with question wording and response options and postsurvey weighting and adjustments..

所有样本调查和民意测验，无论是否使用概率抽样，都会受到其他多种误差来源的影响，这些误差通常无法量化或估计，包括但不限于覆盖误差、与无响应相关的误差、与问题措辞和回答选项相关的误差以及调查后的加权和调整。

About The Harris Poll

关于哈里斯民意调查

The Harris Poll is a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. It works with clients in three primary areas: building twenty-first-century corporate reputation, crafting brand strategy and performance tracking and earning organic media through public relations research.

哈里斯民意调查是一家全球咨询和市场研究公司，致力于揭示现代社会的真实价值观，以激励领导者创造更美好的未来。该公司主要在三个领域为客户提供服务：打造21世纪企业声誉、制定品牌战略与绩效跟踪，以及通过公共关系研究赢得有机媒体关注。

One of the longest running surveys in the U.S., The Harris Poll has tracked public opinion, motivations and social sentiment since 1963 and is now part of Stagwell, the challenger holding company built to transform marketing..

美国历时最长的调查之一，哈里斯民意调查自1963年以来一直追踪公众意见、动机和社会情绪，现在它是挑战者控股公司Stagwell的一部分，该公司旨在变革营销。

About Tardive Dyskinesia Awareness Week

关于迟发性运动障碍宣传周

Since it began in 2018, all 50 states,

自从2018年开始，全美50个州，

Washington, D.C.

华盛顿特区

, and various mental health advocacy organizations have recognized the first full week of May as Tardive Dyskinesia (TD) Awareness Week, which acknowledges the approximately 800,000 adults in

，各种心理健康倡导组织已经将五月的第一个完整周认定为迟发性运动障碍（TD）认知周，这一周承认了大约80万名成年人在…

the United States

美国

living with TD, an involuntary movement disorder associated with taking antipsychotic medication commonly prescribed to treat mental illnesses. Participants in TD Awareness Week help to educate people across the U.S. on the potential physical, social and emotional consequences of TD and the importance of speaking with a healthcare provider about routine screening, the occurrence and impact of the uncontrollable movements and available treatment options..

与服用常用于治疗精神疾病的抗精神病药物相关的不自主运动障碍（TD）共同生活。参与TD宣传周的人员帮助美国各地的人们了解TD可能带来的身体、社交和情感影响，并强调与医疗保健提供者讨论定期筛查、不自主运动的发生及其影响以及可用的治疗选择的重要性。

As part of Neurocrine Biosciences' commitment to TD education, more information is available at

作为Neurocrine Biosciences对TD教育承诺的一部分，更多信息可在此处获取：

Neurocrine.com/TD-Awareness

, and resources are available at

，资源可在以下位置获得：

TalkAboutTD.com.

TalkAboutTD.com。

These resources can help patients and care partners understand TD and recognize its symptoms, request support and have a conversation with their healthcare provider about ways to manage their TD, including treatment options. Healthcare professionals can also visit

这些资源可以帮助患者和护理伙伴了解 TD 并识别其症状，寻求支持，并与医疗保健提供者讨论管理 TD 的方法，包括治疗选项。医疗保健专业人员也可以访问。

MIND-TD.com

心灵TD.com

to learn about differential diagnosis of TD and other movement disorders. For more information, follow and join the conversation online by sharing #TDAwarenessWeek #Screen4TD.

了解关于TD和其他运动障碍的鉴别诊断。欲了解更多信息，请通过分享#TDAwarenessWeek #Screen4TD在线关注并加入对话。

About Tardive Dyskinesia

关于迟发性运动障碍

Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain.

迟发性运动障碍 (TD) 是一种运动障碍，其特征是面部、躯干和/或其他身体部位出现无法控制、异常且重复的运动，这些运动可能会造成干扰并对患者产生负面影响。该病症与服用某些精神健康药物（抗精神病药）有关，这些药物有助于控制大脑中的多巴胺受体。

Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.

服用常用于治疗重度抑郁症、双相情感障碍、精神分裂症和分裂情感性障碍等精神疾病的抗精神病药物，以及其他用于治疗胃肠道疾病的处方药（如甲氧氯普胺和丙氯哌嗪），与迟发性运动障碍（TD）有关。在患有TD的患者中，这些治疗被认为会导致控制运动的大脑区域出现不规则的多巴胺信号传导。

The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S..

TD的症状可能很严重，而且往往持续存在且不可逆。据估计，美国至少有80万名成年人受到TD的影响。

About Neurocrine Biosciences, Inc.

关于Neurocrine Biosciences公司

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders.

Neurocrine Biosciences是一家领先的神经科学-focused生物制药公司，拥有一个简单的使命：减轻高需求人群的痛苦。我们致力于为那些尚未得到充分治疗的神经、神经内分泌和神经精神疾病患者发现并开发生命改变的治疗方法。

The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas.

公司多样化的产品组合包括FDA批准的治疗迟发性运动障碍、亨廷顿病相关的舞蹈症、经典先天性肾上腺增生、子宫内膜异位症*和子宫肌瘤*的药物，以及一个强大的研发管线，涵盖多个处于中期至晚期临床开发阶段的化合物，遍布我们的核心治疗领域。

For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit .

三十年来，我们运用自己对神经科学以及大脑和身体系统之间相互联系的独特见解来治疗复杂疾病。我们不懈地研发药物以减轻衰弱性疾病和病症带来的负担，因为您值得拥有勇敢的科学。欲了解更多信息，请访问。

neurocrine.com

, and follow the company on

，并在以下平台关注该公司

领英

，

and

和

Facebook

. (*

。 (*

in collaboration with AbbVie

与艾伯维合作

)

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

NEUROCRINE BIOSCIENCES 徽标、NEUROCRINE 和 YOU DESERVE BRAVE SCIENCE 是 Neurocrine Biosciences, Inc. 的注册商标。

Forward-Looking Statements

前瞻性声明

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from treating patients with tardive dyskinesia (TD) with a vesicular monoamine transporter 2 (VMAT2) inhibitor and the Company's plans to encourage awareness that may help address the needs of people living with TD, and the value that such awareness may bring to patients.

本新闻稿除包含历史事实外，还包含涉及若干风险和不确定性的前瞻性陈述。这些陈述包括但不限于：有关使用囊泡单胺转运体 2（VMAT2）抑制剂治疗迟发性运动障碍（TD）患者的潜在益处的陈述、公司计划提高可能有助于满足 TD 患者需求的认知，以及这种认知可能为患者带来的价值。

Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: whether the survey findings represent the experiences of people living with TD; whether the Company can successfully encourage awareness that may help address the unmet needs of people living with TD; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA; whether INGREZZA receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA; risks that post-approval INGREZZA commitments or requirements may be delayed; risks that INGREZZA may be .

可能导致实际结果与前瞻性声明中所述或暗示的结果存在重大差异的因素包括但不限于以下：调查结果是否代表了TD患者的生活体验；公司是否能够成功提升可能有助于解决TD患者未满足需求的认知；与Neurocrine Biosciences业务和财务相关的风险和不确定性，以及与INGREZZA商业化相关的风险和不确定性；INGREZZA是否能从第三方支付方获得足够的报销；与竞争产品和技术变革相关的风险和不确定性可能会限制对INGREZZA的需求；公司依赖第三方进行与INGREZZA相关的开发和制造活动所带来的风险，以及公司管理这些第三方的能力；关于INGREZZA或其他候选产品的额外监管提交可能不会发生或未能及时提交的风险；FDA或其他监管机构可能对INGREZZA做出不利决定的风险；INGREZZA的批准后承诺或要求可能被延迟的风险；INGREZZA可能存在其他风险。

December 31, 2024

2024年12月31日

. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

Neurocrine Biosciences否认有任何义务在本日期之后更新本新闻稿中包含的声明，除非法律要求。

*The TD patient survey was conducted online in the U.S. by The Harris Poll on behalf of Neurocrine Biosciences. The survey included 150 patients with mild/moderate TD (n=112) or severe TD (n=38) aged 18 or older who have been diagnosed with TD by a healthcare provider. The survey was conducted from .

*TD患者调查由哈里斯民意调查公司在线上进行，代表Neurocrine生物科学公司在美国实施。调查包括150名被医疗保健提供者诊断为TD的18岁或以上患者，其中轻度/中度TD患者（n=112）或重度TD患者（n=38）。调查时间为。

December 12, 2024

2024年12月12日

至

December 31, 2024

2024年12月31日

。

REFERENCES

参考文献

Harris Insights & Analytics. (2025). Tardive Dyskinesia (TD) Patient Survey [Unpublished survey]. The Harris Poll.

哈里斯洞察与分析。（2025）。迟发性运动障碍（TD）患者调查［未发表的调查］。哈里斯民意调查。

Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder.